Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun 30;2017(2):11.
doi: 10.21542/gcsp.2017.11.

Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports

M Salem  1 , T Reichlin  2 , D Fasel  3 , A Leuppi-Taegtmeyer  1
Affiliations
Review

Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports

M Salem et al. Glob Cardiol Sci Pract. .

Abstract

Background: Literature about torsade de pointes induced by azole antifungal agents is scarce, despite the well-known association. Furthermore, little is known about the latency time between commencing an azole antifungal agent and developing torsade de pointes. The objectives of the present study were therefore to identify all cases of torsade de pointes associated with systemic azole antifungal use reported to the WHO monitoring centre (Uppsala, Sweden) and to determine the latency times between commencing the azole and developing torsade de pointes. Methods: Investigator-driven, retrospective, descriptive analysis of post-marketing pharmacovigilance data regarding systemic azole antifungal agents and the development of torsade de pointes reported to the WHO monitoring centre 1995-2015. Results: 191 cases were reported as follows: fluconazole 130, itraconazole 22, ketoconazole 5, posaconazole 1, voriconazole 33. More than half of all cases involved concomitant suspected or interacting drugs. The median latency times between starting the azole and developing torsade de pointes ranged from 1 (posaconazole) - 9.5 days (itraconazole), range <1-250). Conclusions: Clinicians should be aware of these features of azole-associated torsade de pointes, avoid interacting drugs if at all possible and monitor at-risk patients.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Age distribution of the 191 reported patients.
Figure 2.
Figure 2.. Top 20 co-reported substances (WHODrug).
See this image and copyright information in PMC

References

    1. Schwartz PJ, Woosley RL. Predicting the unpredictable: Drug-induced QT prolongation and Torsades de Pointes. J Am Coll Cardiol. 2016;67:1639–1650. - PubMed
    1. De Bruin ML, Pettersson M, Meyboom RH, Hoes AW, Leufkens HG. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J. 2005;26:590–597. - PubMed
    1. Owens Jr RC, Nolin TD. Antimicrobial-associated QT interval prolongation: Pointes of interest. Clin Infect Dis. 2006;43:1603–1611. - PubMed
    1. Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation. 2002;105:1943–1948. - PubMed
    1. Straus SM, Sturkenboom MC, Bleumink GS, Dieleman JP, van der Lei J, de Graeff PA, et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J. 2005;26:2007–2012. - PubMed

LinkOut - more resources